Physician profile
John Teteris
NPI 1669414637
$5,062.26
in general payments reported to CMS, 2019-2025
47 companies · $516 in 2025
The $516 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $191 · 2021: $813 · 2022: $995 · 2023: $1,627 · 2024: $619 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,109.18 | 2019-2025 | Ubrelvy, Orilissa, Qulipta |
| Myriad Women'S Health, INC. | $677.13 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $344.52 | 2019-2023 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Agile Therapeutics, INC. | $246.33 | 2021-2024 | Twirla |
| Mayne Pharma Commercial LLC | $215.25 | 2021-2025 | |
| Daiichi Sankyo INC. | $208.04 | 2021-2024 | Injectafer |
| Gynesonics, INC. | $194.57 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $190.95 | 2021-2024 | Slynd |
| Minerva Surgical, INC | $184.15 | 2019-2025 | |
| Aspira Women'S Health INC | $167.97 | 2021-2024 | Ova1 |
| Channel Medsystems, INC. | $134.41 | 2022-2023 | |
| Novo Nordisk INC | $132.19 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Therapeuticsmd, INC. | $107.24 | 2019-2022 | |
| Pfizer INC. | $90.11 | 2022-2024 | |
| Biogen, INC. | $72.88 | 2024-2025 | Zurzuvae |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.85 | 2024-2025 | Zepbound |
| Evofem Biosciences, INC. | $58.09 | 2021-2022 | |
| Caldera Medical, INC | $54.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.35 | 2023-2024 | |
| Astellas Pharma US INC | $52.86 | 2022-2024 | Myrbetriq |
| Myovant Sciences INC. | $49.32 | 2021-2022 | |
| Boston Scientific Corporation | $41.12 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.13 | 2022 | |
| Amgen INC. | $38.55 | 2024-2025 | Evenity, Prolia, Prolia |
| Sumitomo Pharma America, INC. | $37.30 | 2024-2025 | Myfembree |
| Millicent US INC | $35.80 | 2024-2025 | Femlyv, Intrarosa |
| Coloplast Corp | $35.39 | 2021-2022 | |
| Meditrina | $32.98 | 2023-2025 | |
| Sanofi Pasteur INC. | $31.76 | 2024 | |
| Merck Sharp & Dohme LLC | $29.72 | 2021 | |
| Coopersurgical, INC. | $29.25 | 2019-2022 | |
| Avion Pharmaceuticals | $28.57 | 2021-2023 | Balcoltra |
| Optumhealth Care Solutions, LLC | $27.61 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Dysis Medical, INC. | $26.70 | 2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Allergan, INC. | $25.75 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $24.16 | 2022 | |
| Medtronic USA, INC. | $21.09 | 2019 | |
| Axsome Therapeutics, INC. | $18.35 | 2025 | Auvelity |
| Aesculap, INC. | $17.81 | 2019 | |
| Duchesnay USA Incorporated | $16.84 | 2019 | |
| Scynexis, INC. | $16.82 | 2022 | |
| Covidien LP | $16.71 | 2019 | |
| Conmed Corporation | $16.57 | 2023 | Airseal |
| Teva Pharmaceuticals USA, INC. | $15.88 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.57 | 2019 | |
| Lupin INC. | $12.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Teteris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.